Brigatinib

Evidence Level: L5

Predicted Indications: 9

Brigatinib

Pharmacist Assessment Report

Brigatinib: ALK tyrosine kinase inhibitor → Gingival fibromatosis (fibromatosis, gingival)

One-Sentence Summary

Brigatinib is an oral tyrosine kinase inhibitor, a next-generation ALK inhibitor used in lung cancer treatment. The TxGNN model predicts it may be relevant to Gingival fibromatosis (fibromatosis, gingival), but no clinical trials and no publications in the data compiled for this report support this prediction, so it rests on the model score alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Gingival fibromatosis (fibromatosis, gingival)
TxGNN Prediction Score	0.9989
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not currently available. Brigatinib is a tyrosine kinase inhibitor, and published work shows it inhibits several kinases beyond ALK in other settings (for example, NF2-deficient tumour models).

The data compiled for this report identify no mechanistic link between brigatinib and gingival fibromatosis. The score of 0.9989 is a model-generated prediction only. Any rationale, such as kinase inhibition affecting fibroblast overgrowth, would be speculative and is not supported by the data. This prediction should be treated as a hypothesis only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 11974F	Alunbrig	Tablet 90 mg	Not recorded in the local data

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (tyrosine kinase inhibitor)
Myelosuppression Risk	Please refer to the Product Information (PI) warnings and precautions
Emetogenicity Classification	Please refer to the Product Information (PI) warnings and precautions
Monitoring Items	Please refer to the Product Information (PI) warnings and precautions
Handling Protection	Please refer to the Product Information (PI) warnings and precautions

Safety Considerations

Label warnings and contraindications are not available in the data compiled for this report; please refer to the TGA-approved Product Information (PI).

Drug Interactions: The interaction screen returned 100 interacting drugs; the first 20 reviewed include the following.

Major: aprepitant, dexamethasone, clarithromycin
Moderate: includes acid-suppressing agents (famotidine, ranitidine, rabeprazole, cimetidine), antidiabetic agents (metformin, pioglitazone, acarbose, canagliflozin, dapagliflozin, alogliptin, albiglutide, acetohexamide, chlorpropamide), loperamide, morphine, cisapride and clotrimazole

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has a high model score but no supporting trials or publications, and no mechanistic link has been identified. The evidence level is L5.

To proceed, the following is needed:

Detailed mechanism of action data for brigatinib
Any preclinical or clinical evidence that directly studies gingival fibromatosis
A biological rationale linking kinase inhibition to the disease
Review of TGA Product Information for safety, warnings and contraindications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.